Claims
- 1. A contact lens having a pharmaceutical agent releasably disposed therein wherein the lens itself comprises a polymer of an unsaturated carboxylic acid ester of salicylic acid, said unsaturated carboxylic acid having up to 24 carbon atoms and 1-4 ethylenic double bonds, or a pharmaceutically acceptable salt of said salicylic acid ester, and wherein the unsaturated carboxylic acid ester group is attached to the benzene ring of the salicylic acid through the phenolic oxygen atom.
- 2. A contact lens according to claim 1 wherein the lens is made of a polymer comprising acryloyl salicylic acid or methacryloyl salicylic acid units or a pharmaceutically acceptable salt of said salicylic acid.
- 3. A contact lens according to claim 1 wherein the unsaturated carboxylic acid contains 16 to 24 carbon atoms.
- 4. A contact lens according to claim 3 wherein the unsaturated carboxylic acid is erucic acid.
- 5. A contact lens according to claim 3 wherein the unsaturated carboxylic acid has 4 ethylenic double bonds.
- 6. A contact lens according to claim 2 wherein the polymer comprises acryloyl salicylic acid units.
- 7. A contact lens according to claim 2 wherein the polymer comprises methacryloyl salicylic acid units.
- 8. A contact lens according to claim 1 wherein the unsaturated carboxylic acid contains 1 ethylenic double bond.
- 9. A contact lens according to claim 8 wherein the unsaturated carboxylic acid contains 16 to 24 carbon atoms.
- 10. A contact lens according to claim 9 wherein the polymer comprises olcoyl salicylic acid units.
- 11. A contact lens according to claim 5 wherein the unsaturated carboxylic acid is arachidonic acid.
- 12. A contact lens according to claim 9 wherein the unsaturated carboxylic acid is selacholeic acid.
- 13. A contact lens according to claim 9 wherein the unsaturated carboxylic acid is palmitoleic acid.
- 14. A contact lens according to claim 1 wherein the unsaturated carboxylic acid ester of salicylic acid has the formula: wherein R is an alkenyl group of 2 to 17 carbon atoms and X is hydrogen or a pharmaceutically acceptable salt thereof.
RELATED APPLICATIONS
This is a divisional of U.S. application Ser. No. 08/970,583, filed Nov. 14, 1997, U.S. Pat. No. 6,037,338, which is a divisional of U.S. application Ser. No. 08/785,979, filed Jan. 21, 1997, now U.S. Pat. No. 5,910,511 issued Jun. 8, 1999, which is a divisional of U.S. application Ser. No. 08/224,718, filed Apr. 8, 1994, now U.S. Pat. No. 5,760,261 issued Jun. 2, 1998, which is a continuation-in-part of U.S. application Ser. No. 07/853,428, filed Mar. 18, 1992, now U.S. Pat. No. 5,346,929 issued Sep. 13, 1994, which is a divisional of U.S. application Ser. 07/486,217, filed Feb. 28, 1990, now U.S. Pat. No. 5,120,089 issued Jun. 9, 1992, the entire disclosures of which are hereby incorporated by reference and relied upon.
US Referenced Citations (13)
Foreign Referenced Citations (1)
Number |
Date |
Country |
158430 |
Jun 1975 |
CS |
Non-Patent Literature Citations (5)
Entry |
Gu et al. Studies on the Hydrolysis of Biocompatible Acrylic Polymers having Aspirin-Moieties. Biomaterials Medical Devices, and Artificial Organs. 11(2-3). Pp. 211-219, 1983.* |
Lide, Physical Constants of Organic Compounds, CRC Handbook of Chemistry and Physics, 1991-92 72nd Edition, pp. 3-457. |
Pala et al, J. Med. Chem., vol. 11, No. 4, pp. 910-911, 1968. |
Maruko Phar. Co., Chemical Abstract, vol. 94, pp. 544,1981, 46974q. |
Hrabak et al., Chemical Abstract, vol. 84 pp. 430, 1976, 16972p. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
07/853428 |
Mar 1992 |
US |
Child |
08/224718 |
|
US |